Development and Evaluation of Solid Lipid Nanoparticles for the Clearance of Aβ in Alzheimer’s Disease

Shivananjegowda, Meghana Goravinahalli; Hani, Umme; Osmani, Riyaz Ali M.; Alamri, Ali H.; Ghazwani, Mohammed; Alhamhoom, Yahya; Rahamathulla, Mohamed; Paranthaman, Sathishbabu; Gowda, Devegowda Vishakante; Siddiqua, Ayesha

doi:10.3390/pharmaceutics15010221

Cited by 9 publications

(5 citation statements)

References 40 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, NLCs are modified SLNs in which the lipid phase consists of liquid lipids (oils) and solids at room temperature . The small size and lipid nature of SLNs and NLCs facilitate crossing the BBB, especially in the leaky tumor vasculature. , Regarding drug delivery to the CNS, both SLNs and NLCs have been confirmed to improve the treatment of several neurological diseases, such as Parkinson’s disease, Alzheimer’s disease, migraine, epilepsy, and brain cancer . Many studies demonstrated the superiority of NLCs and SLNs over other nanoparticles (e.g., PLGA NPs) to promote targeted delivery of drugs to the brain due to their lipid properties. − …”

Section: Permeation Mechanisms Of Nanoparticles Capable Of Crossing T...mentioning

confidence: 99%

Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier

Zha,

Liu,

et al. 2024

ACS Nano

View full text Add to dashboard Cite

The blood−brain barrier (BBB) is a specialized semipermeable structure that highly regulates exchanges between the central nervous system parenchyma and blood vessels. Thus, the BBB also prevents the passage of various forms of therapeutic agents, nanocarriers, and their cargos. Recently, many multidisciplinary studies focus on developing cargo-loaded nanoparticles (NPs) to overcome these challenges, which are emerging as safe and effective vehicles in neurotheranostics. In this Review, first we introduce the anatomical structure and physiological functions of the BBB. Second, we present the endogenous and exogenous transport mechanisms by which NPs cross the BBB. We report various forms of nanomaterials, carriers, and their cargos, with their detailed BBB uptake and permeability characteristics. Third, we describe the effect of regulating the size, shape, charge, and surface ligands of NPs that affect their BBB permeability, which can be exploited to enhance and promote neurotheranostics. We classify typical functionalized nanomaterials developed for BBB crossing. Fourth, we provide a comprehensive review of the recent progress in developing functional polymeric nanomaterials for applications in multimodal bioimaging, therapeutics, and drug delivery. Finally, we conclude by discussing existing challenges, directions, and future perspectives in employing functionalized nanomaterials for BBB crossing.

show abstract

Section: Permeation Mechanisms Of Nanoparticles Capable Of Crossing T...mentioning

confidence: 99%

Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier

Zha,

Liu,

et al. 2024

ACS Nano

View full text Add to dashboard Cite

show abstract

“…Based on the positive results obtained from various in vitro characterizations of SLNs, it was concluded that they can be used as a useful carrier for delivering drugs across the blood-brain barrier (BBB). 59…”

Section: Lipid Nanoparticlesmentioning

confidence: 99%

Nanotechnology-based drug delivery systems for treatment of knee injuries and Alzheimer’s disease – a review

Brenckman,

Hossain,

Ravindra

2023

MSEIJ

View full text Add to dashboard Cite

The effective treatment of human illnesses relies on the ability to deliver therapeutic compounds to diseased sites in a highly efficient manner. However, conventional therapeutic strategies often require high systemic administration due to non-specific biodistribution and rapid metabolism of free drug molecules before they can reach their intended targets which leads to undesirable side effects. Nanotechnology offers a solution to mitigate these issues by allowing the development of drug delivery systems (DDS) within the nanometer size range, which can alter the pharmacological and therapeutic effects of drug molecules. These novel DDS have several advantages over traditional large-scale systems, including altered pharmacokinetic behavior and improved payload, owing to their small size. Moreover, their surface chemistry can be easily modified to attach targeting and therapeutic molecules for specific curative and therapeutic applications. In this comprehensive review, we explore and present the potential of nanoparticles as a highly effective drug delivery system for the treatment of knee injuries and Alzheimer’s disease. With the aim of addressing the challenges that are associated with drug delivery, nanotechnology has emerged as an increasingly important area of research. Scientists have conducted extensive investigations into nanosystems with varying compositions and biological properties for use in drug delivery applications. In order to ensure efficient drug delivery, it is critical to understand how nanomaterials interact with the biological environment, target cell-surface receptors, release drugs, administer multiple drugs, and maintain the stability of therapeutic agents. The recognition and appreciation of the molecular mechanisms that are involved in cell signaling in relation to the disease under investigation is of fundamental importance.

show abstract

“…A tricyclic antidepressant (TCI) is also used for neuroleptic pain . AMX is also used to reduce antibiotic resistance and inhibit mycobacterial infections . AMX is an N-desmethyl derivative of loxapine with noradrenaline reuptake inhibition, 5-HT receptor antagonism, and dopamine D2 receptor antagonism .…”

Section: Introductionmentioning

confidence: 99%

“…SLNs and other nanoparticle formulations can increase drug bioavailability. In recent studies, memantine hydrochloride (MeHCl) and tramiprosate (TMPS)-loaded solid lipid nanoparticles were prepared to treat Alzheimer’s disease . SLN is a suitable delivery system for poorly aqueous-soluble drugs due to its biocompatible lipids and ability to entrap lipophilic molecules.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Amoxapine-Loaded Solid Lipid Nanoparticles with Superior Preclinical Pharmacokinetics for Better Brain Delivery: LC-MS/MS and GC-MS Analysis

Pawar

Gawali

Kulhari

et al. 2023

ACS Chem. Neurosci.

View full text Add to dashboard Cite

The tricyclic antidepressant amoxapine (AMX) has been reported for a rapid onset of action compared to other cyclic antidepressants. It has very low solubility and bioavailability due to first-pass metabolism. Therefore, we planned to develop solid lipid nanoparticles (SLNs) of AMX using a single emulsification method to increase its solubility and bioavailability. HPLC and LC-MS/MS methods were developed further to quantify AMX in the formulation, plasma, and brain tissue samples. The formulation was studied for entrapment efficiency, loading, and in vitro drug release. Particle size and ζ potential analyses, AFM, SEM, TEM, DSC, and XRD were used for further characterization. In vivo oral pharmacokinetic and brain pharmacokinetic studies were performed using Wistar rats. The entrapment and loading efficiencies of AMX in SLNs were 85.8 ± 3.42 and 4.5 ± 0.45%, respectively. The developed formulation had a mean particle size of 151.5 ± 7.02 nm and a polydispersity index of 0.40 ± 0.11. DSC and XRD results indicated that AMX was incorporated into the nanocarrier system in an amorphous form. SEM, TEM, and AFM studies of AMX-SLNs confirmed the particles’ spherical shape and nanoscale size. AMX solubility increased by approx. 2.67 times compared to the pure drug. The developed LC-MS/MS method was successfully applied to the oral and brain pharmacokinetic study of AMX-loaded SLNs in rats. Oral bioavailability was enhanced 1.6 times compared to the pure drug. The peak plasma concentrations of pure AMX and AMX-SLNs were 617.4 ± 137.4 and 1043.5 ± 150.2 (ng/mL), respectively. AMX-SLNs showed more than 5.8 times brain concentration compared to the pure drug. Based on the findings, it appears that utilizing a solid lipid nanoparticle carrier to transport AMX can be a highly effective delivery method with improved pharmacokinetic properties in the brain. This approach may prove valuable for future antidepressant treatment.

show abstract

Development and Evaluation of Solid Lipid Nanoparticles for the Clearance of Aβ in Alzheimer’s Disease

Cited by 9 publications

References 40 publications

Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier

Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier

Nanotechnology-based drug delivery systems for treatment of knee injuries and Alzheimer’s disease – a review

Amoxapine-Loaded Solid Lipid Nanoparticles with Superior Preclinical Pharmacokinetics for Better Brain Delivery: LC-MS/MS and GC-MS Analysis

Contact Info

Product

Resources

About